-Omics and Prognostic Markers
Neuro-Oncology(2010)
摘要
BACKGROUND: Several blood biomarkers have been established for the early diagnosis, screening, and follow-up of non-central nervous system cancers.However, there is lack of knowledge on biochemical blood alterations in brain tumor patients.METHODS: We prospectively studied 109 adult brain tumor patients with diffuse low-grade glioma (WHO II, n ¼ 8), anaplastic glioma (WHO III, n ¼ 11), glioblastoma (WHO IV, n ¼ 34), meningioma (WHO I, n ¼ 11), atypical/anaplastic meningioma (WHO II-III, n ¼ 6), and intracerebral metastasis (ICM, n ¼ 39).In each case, we collected plasma samples maximally 3 days before any mode of neurosurgical intervention (first operation in 73 cases, radiosurgery in 25 cases of ICM).Plasma concentrations of distinct markers including S100B, neuropeptide Y (NPY), secretagogin (SCGN), interleukin 8 (IL8), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), placental growth factor (PIGF), and glial fibrillary acidic protein (GFAP) were analyzed using commercially available ELISA kits.RESULTS: GFAP was detectable in 12 of 34 glioblastoma patients (median: 0.31 ng/ml; range: 0.03-2.17ng/ml), while all other plasma samples were GFAP negative except one anaplastic oligoastrocytoma (6.29 ng/ml) and one ICM (0.54 ng/ml; plasma P , 0.001, chi-square test).Median IL8 and PIGF concentrations were significantly higher in the ICM patients (median: ,level of detection (LOD); range: ,LOD-309.98pg/ml for IL8; median: 10.2 pg/ml; range: ,LOD-133.3pg/ml for PIGF) when compared with meningioma (median: ,LOD; range: ,LOD-53.98 pg/ml for IL8; median: 7.9 pg/ml; range: ,LOD-12 pg/ml for PIGF) and glioma (median: ,LOD; range: ,LOD-28.27pg/ml for IL8; median: 2.7 pg/ml; range: ,LOD-14.1pg/ml for PIGF) patients, respectively (P , 0.001, Kruskal-Wallis-Test). S100B, NPY, SCGN, BDNF, and GDNF concentrations showed no significant difference between patient groups (P .0.05).CONCLUSION: Our results suggest a potential role of IL8 and PIGF in the pathobiology of brain metastases and highlight the potential usability of GFAP as a plasma biomarker in glioblastoma patients.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要